Chargement en cours...
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus...
Enregistré dans:
| Publié dans: | Infect Dis Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4811835/ https://ncbi.nlm.nih.gov/pubmed/26831328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-016-0103-4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|